Bupropion Hydrochloride is a norepinephrine-dopamine reuptake inhibitor indicated for major depressive disorder, seasonal affective disorder and smoking cessation. We supply it to US manufacturers of tablets, sustained-release tablets and extended-release tablets.
Data from PubChem (CID 62884) and FDA’s substance registry
CAS number
31677-93-7
Molecular formula
C13H19Cl2NO
Molecular weight
276.2g/mol
FDA UNII
IUPAC name
2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one;hydrochloride
InChIKey
HEYVINCGKDONRU-UHFFFAOYSA-N
- Appearance
- White or almost white crystalline powder.
- Solubility
- Freely soluble in water, and soluble in alcohol and in 0.1 N hydrochloric acid.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Hygroscopic and prone to degrade with moisture, so water content and packaging matter. Most demand is for extended-release tablets.
On the US market
- Reference product
- WellbutrinNDA 018644
- Approved ANDAs
- 38 with a marketed product
- Approved forms and strengths
- Extended-release tablet 100 mg, 150 mg, 200 mg, 300 mg, 450 mg
- Tablet 75 mg, 100 mg
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com
Sertraline Hydrochloride
Selective serotonin reuptake inhibitor (SSRI)
CAS 79559-97-0Escitalopram Oxalate
Selective serotonin reuptake inhibitor (SSRI)
CAS 219861-08-2Duloxetine Hydrochloride
Serotonin-norepinephrine reuptake inhibitor (SNRI)
CAS 136434-34-9Trazodone Hydrochloride
Serotonin antagonist and reuptake inhibitor
CAS 25332-39-2